title: Caffeic acid phenethyl ester decreases the level of S-100B protein after middle cerebral artery [correction for after] occlusion in rabbits.
abstract: Effects of caffeic acid phenethyl ester (CAPE) on the serum S-100B levels were studied as an index for brain damage after permanent middle cerebral artery (MCA) occlusion in rabbits. Twenty rabbits were divided into four groups (n=5): control, sham, non-treatment and CAPE. The right MCA was occluded using a microsurgical procedure with bipolar coagulation and was then transected in non-treatment and CAPE groups. The rabbits in the sham group underwent a surgical procedure but the MCA was not occluded. No surgery was performed in the control group. CAPE was administered after MCA occlusion at the dose of 10 microg/kg, once a day intraperitoneally for 7 days in the CAPE group. Serum S-100B levels were determined on days 1, 2, 4 and 7. Serum S-100B level was significantly increased following permanent MCA occlusion. Posttreatment of CAPE significantly reduced the serum S-100B level. This study demonstrated that CAPE is capable of attenuating increased serum S-100B level induced by MCA occlusion in rabbits. CAPE may be useful as a neuroprotective agent.
authors: Department of Neurosurgery, Tayfur Ata Sökmen Medical Faculty, Mustafa Kemal University, Hatay, Turkey. yserarslan@yahoo.com
authors: Yurdal
authors: Y
authors: Serarslan
authors: Ramazan
authors: R
authors: Bal
authors: Muhammed Enes
authors: ME
authors: Altuğ
authors: Tünay
authors: T
authors: Kontaş
authors: Ismet Murat
authors: IM
authors: Melek
mesh_terms: D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D001925:Brain Damage, Chronic / Q000097:blood* / Q000188:drug therapy; D002109:Caffeic Acids / Q000494:pharmacology* / Q000627:therapeutic use; D020244:Infarction, Middle Cerebral Artery / Q000097:blood* / Q000188:drug therapy; D007274:Injections, Intraperitoneal; D008297:Male; D009414:Nerve Growth Factors / Q000097:blood*; D018696:Neuroprotective Agents / Q000494:pharmacology* / Q000627:therapeutic use; D010626:Phenylethyl Alcohol / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D011817:Rabbits; D064568:S100 Calcium Binding Protein beta Subunit; D009418:S100 Proteins / Q000097:blood*
chemical_list: D015415:Biomarkers; D002109:Caffeic Acids; D009414:Nerve Growth Factors; D018696:Neuroprotective Agents; D064568:S100 Calcium Binding Protein beta Subunit; D009418:S100 Proteins; C055494:caffeic acid phenethyl ester; D010626:Phenylethyl Alcohol